Home/Pipeline/MemorEM

MemorEM

Alzheimer's Disease

Phase 2Active

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2

Status

Active

Company

NeuroEM Therapeutics

About NeuroEM Therapeutics

NeuroEM Therapeutics is pioneering a first-in-class, non-invasive medical device for Alzheimer's disease, having received FDA Breakthrough Device designation. Its MemorEM device administers transcranial electromagnetic waves (TEMT-RF) to disaggregate toxic beta-amyloid and p-tau oligomers, rebalance the immune system, and boost cellular energy in the brain. The company has reported promising Phase 2 data showing cognitive reversal in a majority of patients and is preparing for pivotal trials. NeuroEM represents a significant shift from pharmaceutical approaches to a technology-driven, at-home treatment paradigm for neurodegenerative diseases.

View full company profile

Therapeutic Areas

Alzheimer's Disease Neurodegenerative Diseases

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active